AGY:LSE-Allergy Therapeutics plc (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 27.00

Change

+1.00 (+3.85)%

Market Cap

GBX 0.17B

Volume

0.17M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

+17.00 (+0.65%)

GBX6.08B 19.95 9.24
INDV:LSE Indivior PLC

+2.60 (+1.71%)

GBX1.11B 16.86 5.40
BXP:LSE Beximco Pharmaceuticals Limite..

+1.00 (+1.32%)

GBX0.71B 13.12 0.10
APH:LSE Alliance Pharma plc

-0.50 (-0.50%)

GBX0.53B 65.40 17.89
BMK:LSE Benchmark Holdings plc

N/A

GBX0.39B N/A 24.13
AMYT:LSE Amryt Pharma plc

-1.50 (-0.89%)

GBX0.30B N/A N/A
SAR:LSE Sareum Holdings plc

N/A

GBX0.25B N/A N/A
EAH:LSE ECO Animal Health Group plc

N/A

GBX0.23B 68.00 17.95
VLG:LSE Venture Life Group plc

N/A

GBX0.12B 37.20 15.38
DNL:LSE Diurnal Group plc

-0.12 (-0.19%)

GBX0.11B N/A N/A

ETFs Containing AGY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 62.41% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.41% 92% A- 95% A
Trailing 12 Months  
Capital Gain 88.81% 86% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.81% 86% B 91% A-
Trailing 5 Years  
Capital Gain 38.46% 54% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.46% 54% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 6.90% 23% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.90% 23% F 47% F
Risk Return Profile  
Volatility (Standard Deviation) 53.02% 69% D+ 27% F
Risk Adjusted Return 13.02% 23% F 35% F
Market Capitalization 0.17B 43% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.90 63% D 34% F
Price/Book Ratio 2.79 71% C- 34% F
Price / Cash Flow Ratio 13.84 21% F 32% F
EV/EBITDA 10.38 67% D+ 59% F
Management Effectiveness  
Return on Equity 12.23% 79% C+ 73% C
Return on Invested Capital 16.67% 100% A+ 88% B+
Return on Assets 5.33% 71% C- 74% C
Debt to Equity Ratio 6.69% 75% C 76% C
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.61 8% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector